{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:57:28Z","timestamp":1791489448953,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":2948,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["BFU2009-0831"],"award-info":[{"award-number":["BFU2009-0831"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["SAF2008-03546"],"award-info":[{"award-number":["SAF2008-03546"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.fertnstert.2014.01.031","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T02:45:39Z","timestamp":1393382739000},"page":"1411-1418.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in\u00a0vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists"],"prefix":"10.1016","volume":"101","author":[{"given":"Hortensia","family":"Ferrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen M.","family":"Garc\u00eda-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Delgado-Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gayt\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pellicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2014.01.031_bib1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMp038106","article-title":"The pathogenesis of the ovarian hyperstimulation syndrome","volume":"349","author":"Kaiser","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0015-0282(16)57656-0","article-title":"Immunoreactive endothelin plasma levels in severe ovar\u00edan hypertimulation s\u00edndrome","volume":"64","author":"Balasch","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tjog.2011.01.014","article-title":"Update on management of ovarian hyperstimulation syndrome","volume":"50","author":"Chen","year":"2011","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/humrep\/10.1.24","article-title":"Interleukin-2 and ovarian hyperstimulation syndrome: a pilot study","volume":"10","author":"Orvieto","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0015-0282(16)57353-1","article-title":"Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome","volume":"63","author":"Goldsman","year":"1995","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0929-6646(08)60162-X","article-title":"Ovarian hyperstimulation syndrome (OHSS): new strategies of prevention and treatment","volume":"107","author":"Chen","year":"2008","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1210\/jc.2007-1512","article-title":"Lysophosphatidic acid up-regulates expression of interluikin-8 and -6 in granulose-lutein cells through its receptors and nuclear factor-KB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome","volume":"9","author":"Chen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib8","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1172\/JCI4814","article-title":"Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome","volume":"102","author":"Levin","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(94)93001-5","article-title":"Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome","volume":"344","author":"McClure","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib10","first-page":"1967","article-title":"Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor\/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome","volume":"80","author":"Neulen","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib11","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1210\/jcem.87.7.8651","article-title":"Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up regulation of vascular endothelial growth factor","volume":"87","author":"Wang","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib12","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1074\/jbc.M002016200","article-title":"Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants","volume":"276","author":"Gille","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/oxfordjournals.humrep.a137103","article-title":"Case report: acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome","volume":"5","author":"Balasch","year":"1990","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib15","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats and this effect is prevented by receptor blockade","volume":"143","author":"G\u00f3mez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.fertnstert.2011.12.046","article-title":"Etiology of OHSS and use of dopamine agonists","volume":"97","author":"Soares","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Saf"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib18","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"\u00c1lvarez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/jcem-47-2-290","article-title":"Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors","volume":"47","author":"Mornex","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy","volume":"135","author":"Morange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/87895","article-title":"The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor","volume":"7","author":"Basu","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib23","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1242\/jcs.053124","article-title":"Dopamine regulates phosphorylation of VEGF receptor 2 by engaging Src-homology-2-domain-containing protein tyrosine phosphatase 2","volume":"122","author":"Sinha","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib24","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low dose dopamine agonist administration blocks VEGF mediated vascular permeability without altering VEGFR-2 dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"G\u00f3mez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib25","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1093\/humrep\/dem315","article-title":"Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study","volume":"22","author":"\u00c1lvarez","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0974-1208.69342","article-title":"Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction","volume":"3","author":"Sherwal","year":"2010","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejogrb.2012.08.008","article-title":"Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study","volume":"165","author":"Shaltout","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib30","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1210\/en.2004-1445","article-title":"Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice","volume":"146","author":"Cristina","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/oxfordjournals.humrep.a137543","article-title":"Cultured human granulosa cells as a model for corpus luteum function: relative roles of gonadotrophin and low density lipoprotein studied under defined culture conditions","volume":"7","author":"Richardson","year":"1992","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/humrep\/des096","article-title":"Efficiency and purity provided by the existing methods for the isolation of luteinized granulosa cells: a comparative study","volume":"27","author":"Ferrero","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/002215540004800216","article-title":"Quantitative immunohistochemistry by measuring cumulative signal strength using commercially available software Photoshop and Matlab","volume":"48","author":"Matkowskyj","year":"2000","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib34","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1210\/jc.2011-0075","article-title":"Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment","volume":"96","author":"G\u00f3mez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib36","series-title":"The mode of action of drugs on cells","author":"Clark","year":"1933"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/oxfordjournals.humrep.a138598","article-title":"Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors","volume":"9","author":"Dahl Lyons","year":"1994","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2014.01.031_bib39","doi-asserted-by":"crossref","first-page":"7997","DOI":"10.1093\/nar\/gkt539","article-title":"VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level","volume":"41","author":"Arcod\u00e9guy","year":"2013","journal-title":"Nucleic Acids Res"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502821400079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502821400079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:13:17Z","timestamp":1762150397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001502821400079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S001502821400079X"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2014.01.031","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in\u00a0vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2014.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}